登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603990 证券简称：麦迪科技 公告编号：2025-081 苏州麦迪斯顿医疗科技股份有限公司 关于取消监事会并修订《公司章程》及废止、新增、修订内部管理制度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 苏州麦迪斯顿医疗科技股份有限公司（以下简称"公司"）于2025年12月12日召开第四届董事会第三十八 次会议，审议通过了《关于取消监事会并修订<公司章程>的议案》《关于新增、废止、修订公司内部 管理制度的议案》；召开第四届监事会第二十次会议，审议通过了《关于取消监事会、废止<监事会议 事规则>并修订<公司章程>的议案》。为进一步规范公司运作，完善公司治理结构，促进公司持续健康 稳定发展，公司根据《中华人民共和国公司法》（以下简称"《公司法》"）《中华人民共和国证券法》 （以下简称"《证券法》"）及《上海证券交易所股票上市规则》《上市公司章程指引》《上海证券交易 所上市公司自律监管指引第1号——规范运作》等相关法律法规和规范性文件的要求，公司拟取消监事 会、废 ...

根据北交所最新披露的信息，2025年12月12日，江苏爱舍伦医疗科技集团股份有限公司IPO的状态从提 交注册变更为注册。 根据北交所最新披露的信息，2025年12月12日，江苏爱舍伦医疗科技集团股份有限公司IPO的状态从提 交注册变更为注册。 ...

Group 1 - The forum "Opportunities and Challenges for Chinese Capital Going Global" highlighted the necessity of systematic support for capital outflow, including regulations, services, and capabilities [1] - The Lingang New Area has introduced nearly 200 institutional innovations in six years, with about half being national firsts, establishing a solid foundation for financial openness and cross-border capital flow [1] - The Shanghai International Financial Center is transitioning from building a system to enhancing functionality under the guidance of the central government's strategy for a strong financial nation [1] Group 2 - The global economy shows signs of recovery driven by trade resilience, investment demand, and certain countries' policy environments, but risks from high valuation market volatility and uncertainties in international capital flows remain [2] - Innovation is identified as the core competitiveness for medical technology companies going global, necessitating international technical standards and cross-border financing support [2] - The demand for cross-border cold chain services is significantly increasing with the acceleration of innovative drugs going abroad, making technical standards and international certification crucial for service export [2] Group 3 - Financial institutions need to provide comprehensive services covering the entire lifecycle of enterprises as the types of companies going global diversify [3] - Companies must proactively identify sensitive areas and adhere to higher compliance standards due to rapidly changing hard rules regarding data cross-border and foreign investment reviews [3]

Core Viewpoint - The Hong Kong stock market is experiencing a new wave of share buybacks, with significant participation from leading technology companies, particularly in the healthcare sector [1][2]. Group 1: Share Buyback Activity - In November, companies listed on the Hong Kong stock market repurchased over 700 million shares, with over 300 million shares repurchased in just the first few trading days of December [1]. - Medical technology company Yidu Tech (02158) has been a prominent player in this buyback trend, repurchasing 155,000 shares at HKD 5.1 per share on December 12, totaling approximately HKD 790,000 [1]. - Yidu Tech has conducted seven buybacks in December, accumulating around 2.11 million shares repurchased, with a total expenditure exceeding HKD 10.8 million [1]. Group 2: Company Performance and Developments - Yidu Tech's buyback activity reflects the company's strong recognition of its own value, supported by improved performance and business expansion [1]. - For the fiscal year 2026, Yidu Tech reported a significant improvement in profitability and operational efficiency, with adjusted EBITDA reaching approximately HKD 54 million, doubling compared to the same period last year [1]. - The company is making strides in AI healthcare innovation, participating in national AI application pilot projects in Beijing and winning bids for clinical research projects, as well as expanding its "Hui Min Bao" business in Hebei and Guangzhou [1].

Core Viewpoint - Yidu Tech (02158) announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1: Share Buyback Details - The company will repurchase 155,000 shares at a total cost of HKD 790,700 [1] - The buyback price per share ranges from HKD 5.09 to HKD 5.11 [1]

Core Insights - The 2025 Medical Value Healthcare Conference and the 6th Taishan Award Ceremony were recently held in Shanghai, focusing on the theme of "AI-driven diagnostic transformation and industry integration" [1] - JD Health showcased its breakthrough achievements in the medical AI field, particularly through its "Jingyi Qianxun" medical model, which emphasizes collaborative innovation and aims to address the challenges of medical accessibility [1] Group 1: Technological Advancements - "Jingyi Qianxun" has achieved comprehensive integration of information from text to imaging, enabling precise extraction of key information from medical records and orders, and constructing complete health profiles [2] - The model demonstrates advanced pixel-level image analysis capabilities, accurately identifying anatomical structures or lesions in medical images, including MRI, endoscopy, and ultrasound [2] - The multi-modal reasoning ability of "Jingyi Qianxun" simulates human diagnostic logic, allowing for reliable diagnostic outputs even from complex medical test results [2] Group 2: Performance Metrics - In authoritative assessments, "Jingyi Qianxun" has shown outstanding performance, achieving 99% in medical calculation ability, 91% in medical Q&A ability, and 91% in text summarization ability, placing it at the forefront of the industry [2] - The model has been validated against a comprehensive evaluation set based on clinical task data from JD Internet Hospital, confirming its leading capabilities in core medical functions [2] Group 3: Future Directions - "Jingyi Qianxun" has evolved from a general base model to a comprehensive model and then to specialized models for specific diseases, reflecting JD Health's long-term commitment to specialized fields [3] - The company plans to continue developing specialized models through technological innovation to enhance medical accessibility, professionalism, and efficiency, aiming to extend quality medical resources to a broader population [3]

Core Insights - The "Jingyi Qianxun" medical AI model by JD Health showcases significant advancements in the healthcare AI sector, particularly in its core capabilities and ecosystem development [1][2]. Group 1: Core Capabilities - "Jingyi Qianxun" is built on three core capabilities: multimodal perception, human-like dialogue, and reliable reasoning, which form the technical foundation for the model [2]. - The upgraded "Jingyi Qianxun 2.0" integrates information from various modalities, including text and imaging, enabling comprehensive health record construction and advanced pixel-level image analysis [2]. - The model's reasoning ability simulates human diagnostic logic, allowing it to analyze complex medical data and provide reliable second opinions, even from distorted medical reports [2]. Group 2: Dialogue and Interaction - The human-like dialogue capability allows "Jingyi Qianxun" to understand vague patient descriptions and provide tailored responses based on individual patient characteristics [3]. - A patient simulator has been developed to enhance dialogue realism, enabling the model to train on diverse user expressions and disease severities, thereby improving interaction quality [3]. Group 3: Performance Metrics - "Jingyi Qianxun" has demonstrated outstanding performance in authoritative evaluations, achieving 99% in medical calculation, 91% in medical Q&A, and 91% in text summarization, positioning it as a leader in the industry [3][4]. - The model has outperformed competitors in 21 evaluation metrics across five major capabilities, confirming its superior medical AI capabilities [4]. Group 4: Specialized Development - JD Health has focused on specialized models by leveraging high-quality online diagnosis data from its internet hospital, ensuring alignment with clinical tasks [5]. - The evolution from a general model to specialized models is supported by collaborations with top medical institutions and the integration of diverse clinical data for training [5]. Group 5: Future Prospects - The ongoing development of "Jingyi Qianxun" aims to bridge the gap between AI capabilities and human clinical cognition, potentially providing high-quality medical services to users in remote areas [6].

1.身份类别 2.信息披露义务人信息 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603716 证券简称：塞力医疗 公告编号：2025-099 转债代码：113601 转债简称：塞力转债 上海盎泽私募基金管理有限公司-盎泽太盈六号私募证券投资基金保证向本公司提供的信息真实、准 确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 一、 信息披露义务人及其一致行动人的基本信息 3.一致行动人信息 上述信息披露义务人无一致行动人。 二、 权益变动触及5%刻度的基本情况 塞力斯医疗科技集团股份有限公司（以下简称"公司"）于2025年10月1日披露的《关于持股5%以上股东 减持股份计划公告》（公告编号：2025-087），5%以上股东上海盎泽私募基金管理有限公司管理的盎 泽太盈六号私募证券投资基金（以下简称"上海盎泽"）因自身投资规划安排，计划于减持股份计划公告 披露日起15个交易日后的三个月（即2025年10月30日至2026年1月29日），通过集中竞价、大宗交易方 式减持不超过所持公司股份4,202,784股，占公司总股 ...

Group 1 - The 14th China Innovation and Entrepreneurship Competition focuses on disruptive technology innovation, featuring 163 projects competing in six cutting-edge tracks, including future manufacturing, information, and materials [1][2] - The competition aims to create a full-chain platform for technology display, capital connection, and industrial landing, promoting efficient collaboration of national innovation resources [2] - The event highlights innovative medical technologies, such as boron neutron capture therapy (BNCT), which targets cancer cells with precision, minimizing damage to healthy tissues and improving patient quality of life [2] Group 2 - Since the competition's debut in Hangzhou, 50 projects have established a presence in the city, demonstrating the effectiveness of the "competition promotes innovation" strategy [3] - Hangzhou is committed to leading industrial innovation through technological advancements, aiming to become a hub for disruptive technology transfer and a major market for tech achievements [2][3] - The local government has developed a support system for disruptive technology innovation, including policies, space, capital, and application scenarios, to facilitate project development and success [3][4]

Kestra Medical Technologies (NasdaqGS:KMTS) Q2 2026 Earnings Call December 11, 2025 04:30 PM ET Company ParticipantsStephanie Piazzola - VP of Equity Research Medical TechnologyVaseem Mahboob - CFOBrian Webster - President and CEODavid Roman - Managing DirectorNeil Bhalodkar - VP of Investor RelationsNone - Company RepresentativeConference Call ParticipantsLarry Biegelsen - Senior Medical Device Equity Research AnalystMarie Thibault - Managing Director and Medical Technology and Digital Health AnalystMichae ...